Funding for this research was provided by:
Guangdong Innovative and Entrepreneurial Research Team Program (2017ZT07S096)
National Natural Science Foundation of China (81700148)
Article History
Received: 17 January 2021
Revised: 21 May 2021
Accepted: 26 May 2021
First Online: 11 June 2021
Conflict of interest
: RPG is a consultant to BeiGene Ltd., Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc. and CStone Pharmaceuticals; advisor to Antegene Biotech LLC, Medical Director, FFF Enterprises Inc.; partner, AZAC Inc.; Board of Directors, Russian Foundation for Cancer Research Support; and Scientific Advisory Board: StemRad Ltd. All other authors declare no competing interests.